For instance, a retrospective study of melanoma patients treated with immune checkpoint inhibitors targeting CTLA-4 and PD1 showed that decreased overall survival was associated with elevated baseline levels of IL6, high neutrophil-to-lymphocyte ratio, and elevated C-reactive protein (CRP) levels [81,82]. This evidence concerns the gene CRP and melanoma.